Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A
3(75.0%)
Phase 1
1(25.0%)
4Total
N/A(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT01925794Not ApplicableCompleted

COBRA PZF™ Coronary Stent for Early Healing, Thrombus Inhibition, Endothelialization and Avoiding Long-Term DAPT

Role: lead

NCT02594501Not ApplicableUnknown

Randomized Trial of COBRA PzF Stenting to Reduce Duration of Triple Therapy

Role: lead

NCT02224235Not ApplicableTerminated

COBRA SHIELD OCT Study

Role: lead

NCT03103620Completed

Safety and Effectiveness Evaluation of COBRA PzF Coronary Stent System: A Post Marketing Observational Registry

Role: lead

NCT00799032Phase 1Completed

The ATLANTA First in Man Study of the Catania Stent

Role: lead

NCT00799344Completed

REVEAL Study: Vessel Healing After Angioplasty

Role: lead

All 6 trials loaded